Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3′-ethynylcytidine treatment of human cancer cells

Akira Sato, Takeshi Takano, Akiko Hiramoto, Tomoharu Naito, Akira Matsuda, Masakazu Fukushima, Yusuke Wataya, Hye-Sook Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A nucleosidic medicine, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine [3′-ethynylcytidine (ECyd)], is a potent inhibitor of RNA polymerase I and shows anticancer activity to various human solid tumors in vitro and in vivo. ECyd is phosphorylated to 3′-ethyntlcytidine 5′-monophosphate by uridine/cytidine kinase 2 (UCK2) and subsequently further to diphosphate and triphosphate (3′-ethyntlcytidine 5′-diphosphate, 3′-ethyntlcytidine 5′-triphosphate). 3′-Ethyntlcytidine 5′-triphosphate is an active metabolite that can inhibit RNA polymerase I competitively, causing cancer cell death. Here, to identify the UCK2 mutation for detecting responder or nonresponder to ECyd, we investigated the relationship between point mutation of the UCK2 gene and response to ECyd in various human solid tumors. We identified several functional point mutations including the splice-site mutation of the UCK2 gene IVS5+5 G>A. In addition, we found that the IVS5+5 G>A variant generates an aberrant mRNA transcript, namely, truncated mRNA was produced and normal mRNA levels were markedly decreased in the ECyd-resistant cancer cell line HT1080. We concluded that these findings strongly suggest that the IVS5+5 G>A variant would affect the expression level of the UCK2 transcript, resulting in decreased sensitivity to ECyd.

Original languageEnglish
Pages (from-to)781-786
Number of pages6
JournalAnti-Cancer Drugs
Volume28
Issue number7
DOIs
Publication statusPublished - May 24 2017

Fingerprint

Uridine Kinase
Mutation
RNA Polymerase I
Diphosphates
Neoplasms
Point Mutation
Messenger RNA
Cytosine
Genes
Cell Death
Medicine
1-(3-C-ethynylribopentofuranosyl)cytosine
Cell Line
triphosphoric acid

Keywords

  • 3′-ethynylcytidine
  • point mutation
  • uridine/cytidine kinase 2

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3′-ethynylcytidine treatment of human cancer cells. / Sato, Akira; Takano, Takeshi; Hiramoto, Akiko; Naito, Tomoharu; Matsuda, Akira; Fukushima, Masakazu; Wataya, Yusuke; Kim, Hye-Sook.

In: Anti-Cancer Drugs, Vol. 28, No. 7, 24.05.2017, p. 781-786.

Research output: Contribution to journalArticle

Sato, Akira ; Takano, Takeshi ; Hiramoto, Akiko ; Naito, Tomoharu ; Matsuda, Akira ; Fukushima, Masakazu ; Wataya, Yusuke ; Kim, Hye-Sook. / Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3′-ethynylcytidine treatment of human cancer cells. In: Anti-Cancer Drugs. 2017 ; Vol. 28, No. 7. pp. 781-786.
@article{ee9b68be45594b7db2e4d95f5854fa0b,
title = "Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3′-ethynylcytidine treatment of human cancer cells",
abstract = "A nucleosidic medicine, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine [3′-ethynylcytidine (ECyd)], is a potent inhibitor of RNA polymerase I and shows anticancer activity to various human solid tumors in vitro and in vivo. ECyd is phosphorylated to 3′-ethyntlcytidine 5′-monophosphate by uridine/cytidine kinase 2 (UCK2) and subsequently further to diphosphate and triphosphate (3′-ethyntlcytidine 5′-diphosphate, 3′-ethyntlcytidine 5′-triphosphate). 3′-Ethyntlcytidine 5′-triphosphate is an active metabolite that can inhibit RNA polymerase I competitively, causing cancer cell death. Here, to identify the UCK2 mutation for detecting responder or nonresponder to ECyd, we investigated the relationship between point mutation of the UCK2 gene and response to ECyd in various human solid tumors. We identified several functional point mutations including the splice-site mutation of the UCK2 gene IVS5+5 G>A. In addition, we found that the IVS5+5 G>A variant generates an aberrant mRNA transcript, namely, truncated mRNA was produced and normal mRNA levels were markedly decreased in the ECyd-resistant cancer cell line HT1080. We concluded that these findings strongly suggest that the IVS5+5 G>A variant would affect the expression level of the UCK2 transcript, resulting in decreased sensitivity to ECyd.",
keywords = "3′-ethynylcytidine, point mutation, uridine/cytidine kinase 2",
author = "Akira Sato and Takeshi Takano and Akiko Hiramoto and Tomoharu Naito and Akira Matsuda and Masakazu Fukushima and Yusuke Wataya and Hye-Sook Kim",
year = "2017",
month = "5",
day = "24",
doi = "10.1097/CAD.0000000000000519",
language = "English",
volume = "28",
pages = "781--786",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3′-ethynylcytidine treatment of human cancer cells

AU - Sato, Akira

AU - Takano, Takeshi

AU - Hiramoto, Akiko

AU - Naito, Tomoharu

AU - Matsuda, Akira

AU - Fukushima, Masakazu

AU - Wataya, Yusuke

AU - Kim, Hye-Sook

PY - 2017/5/24

Y1 - 2017/5/24

N2 - A nucleosidic medicine, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine [3′-ethynylcytidine (ECyd)], is a potent inhibitor of RNA polymerase I and shows anticancer activity to various human solid tumors in vitro and in vivo. ECyd is phosphorylated to 3′-ethyntlcytidine 5′-monophosphate by uridine/cytidine kinase 2 (UCK2) and subsequently further to diphosphate and triphosphate (3′-ethyntlcytidine 5′-diphosphate, 3′-ethyntlcytidine 5′-triphosphate). 3′-Ethyntlcytidine 5′-triphosphate is an active metabolite that can inhibit RNA polymerase I competitively, causing cancer cell death. Here, to identify the UCK2 mutation for detecting responder or nonresponder to ECyd, we investigated the relationship between point mutation of the UCK2 gene and response to ECyd in various human solid tumors. We identified several functional point mutations including the splice-site mutation of the UCK2 gene IVS5+5 G>A. In addition, we found that the IVS5+5 G>A variant generates an aberrant mRNA transcript, namely, truncated mRNA was produced and normal mRNA levels were markedly decreased in the ECyd-resistant cancer cell line HT1080. We concluded that these findings strongly suggest that the IVS5+5 G>A variant would affect the expression level of the UCK2 transcript, resulting in decreased sensitivity to ECyd.

AB - A nucleosidic medicine, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine [3′-ethynylcytidine (ECyd)], is a potent inhibitor of RNA polymerase I and shows anticancer activity to various human solid tumors in vitro and in vivo. ECyd is phosphorylated to 3′-ethyntlcytidine 5′-monophosphate by uridine/cytidine kinase 2 (UCK2) and subsequently further to diphosphate and triphosphate (3′-ethyntlcytidine 5′-diphosphate, 3′-ethyntlcytidine 5′-triphosphate). 3′-Ethyntlcytidine 5′-triphosphate is an active metabolite that can inhibit RNA polymerase I competitively, causing cancer cell death. Here, to identify the UCK2 mutation for detecting responder or nonresponder to ECyd, we investigated the relationship between point mutation of the UCK2 gene and response to ECyd in various human solid tumors. We identified several functional point mutations including the splice-site mutation of the UCK2 gene IVS5+5 G>A. In addition, we found that the IVS5+5 G>A variant generates an aberrant mRNA transcript, namely, truncated mRNA was produced and normal mRNA levels were markedly decreased in the ECyd-resistant cancer cell line HT1080. We concluded that these findings strongly suggest that the IVS5+5 G>A variant would affect the expression level of the UCK2 transcript, resulting in decreased sensitivity to ECyd.

KW - 3′-ethynylcytidine

KW - point mutation

KW - uridine/cytidine kinase 2

UR - http://www.scopus.com/inward/record.url?scp=85019672694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019672694&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000519

DO - 10.1097/CAD.0000000000000519

M3 - Article

VL - 28

SP - 781

EP - 786

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 7

ER -